Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
July 19 2019 - 9:19AM
Dow Jones News
By Colin Kellaher
Gilead Sciences Inc. (GILD) on Friday said it licensed three
preclinical antiviral programs from Novartis AG (NVS), including
investigational agents with the potential to treat human
rhinovirus, influenza and herpes viruses.
The Foster City, Calif., biopharmaceutical said it will acquire
exclusive global rights to develop and commercialize novel small
molecules against three undisclosed targets.
Gilead said it will make an upfront payment to Novartis, adding
that the Swiss drugmaker is eligible to receive up to an additional
$291 million in potential development and commercial milestone
payments, along with royalties on product sales.
Gilead earlier this week said it will pay $5.1 billion to boost
its stake in Galapagos NV (GLPG) and gain rights outside Europe to
the Belgian biotechnology company's treatments in development.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 19, 2019 09:04 ET (13:04 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024